TOBI Podhaler is for people 6 years and older with cystic fibrosis (CF), Pseudomonas aeruginosa (Pa), and forced expiratory volume in 1 second (FEV1) 25% to 80% predicted and who do not have Burkholderia cepacia.1

ON-THE-GO TOBI PODHALER DEVICE HELPS YOU FIGHT Pa

For appropriate patients

WHY CHOOSE TOBI PODHALER?

IMPROVED LUNG FUNCTION

IN A CLINICAL TRIAL VS PLACEBO

FEWER RESPIRATORY-RELATED HOSPITALIZATIONS

IN A CLINICAL TRIAL VS PLACEBO

ADMINISTERED IN 2-7 MINUTES*

PORTABLE | CLEANUP WITH MINIMAL NUMBER OF STEPS

*As observed in a clinical trial.

ESTABLISHED SAFETY PROFILE

IN A CLINICAL TRIAL VS TOBI® NEBULIZER SOLUTION

Clinical trial program evaluated safety in 425 patients with CF.

PODCARE+®

ENHANCED CO-PAY AND INSURANCE SUPPORT PROGRAM.

LIMITATIONS APPLY.

Receive instructions and helpful tips on how to use your TOBI Podhaler to reinforce the training you received from
your doctor

Learn more

Podcare+ can help eligible patients with co-pay assistance, insurance, and specialty pharmacy support.

Learn more

REAL PATIENT STORIES

Meet real patients and learn how they manage with TOBI Podhaler.

Watch videos

USING TOBI PODHALER

Watch a video on how to use TOBI Podhaler.

Watch video

TOBI Podhaler was evaluated for safety in 425 patients with CF exposed to at least 1 dose of TOBI Podhaler, including 273 patients who were exposed across 3 cycles. The most common side effects of TOBI Podhaler include cough, worsening of lung problems or cystic fibrosis, productive cough, shortness of breath, fever, sore throat, changes in voice (hoarseness), coughing up blood, headache, and altered taste.1

Valid only for those with commercial insurance. Offer not valid under Medicare, Medicaid, or any other federal or state program, for cash-paying patients, where product is not covered by patient's commercial insurance, or where plan reimburses you for entire cost of your prescription drug. Offer is not valid where prohibited by law. Valid only in the US and Puerto Rico. This program is not health insurance. Offer may not be combined with any other rebate, coupon, or offer. Novartis reserves the right to rescind, revoke or amend the program without notice. Patient certifies responsibility for complying with applicable limitations, if any, of any commercial insurance and reporting receipt of program rewards, if necessary, to any commercial insurer. Patient pays a $0 co-pay for each use of TOBI Podhaler and Novartis pays up to $14,000 annually. This program is subject to termination or modification at any time.

Reference: 1. TOBI Podhaler [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2016.